Introducing Cognivia Signal: Real-Time Behavioral Risk Intelligence for Clinical Trials
Cognivia launches the world’s first real-time behavioral risk intelligence dashboard—Cognivia Signal—empowering clinical teams to see what’s coming before…
News
News
News
New Study Validates Cognivia’s Approach to Reducing Noise in Pain and Mood Trials
New Publication in The Journal of Pain Demonstrates Scalable Method to Improve Measurement of Subjective Endpoints in Clinical Trials Mont-Saint-Guibert,…
News
New Article Uncovering Behavioral Science’s Role in Successful Obesity Trials Published inClinical Trial Vanguard
As the global obesity drug market accelerates toward an estimated $200 billion valuation, sponsors face more than just…
News
Cognivia Poster Reveals 35% Precision Gain in Acute Pain RCTs Using Placebell Covariates
At the United States Association for the Study of Pain 2025 conference, Cognivia presented compelling new data from…
News
New Evidence for Placebell and Compl-AI in Type 1 Diabetes
At the recent 2025 Advanced Technologies & Treatments for Diabetes congress in Amsterdam, Cognivia presented two new scientific posters demonstrating…
Insights
Discussion on the Use of Placebell and FDA’s Feedback
Cognivia recently initiated a discussion with the FDA through the “Innovative Science and Technology Approaches for New Drugs…